Keith Cooper is a successful entrepreneur with more than 25 years’ experience running venture capital-backed technology companies. He is currently CEO of Revolutionary Clinics (RC), a leading medicinal cannabis company in Massachusetts. RC has an active cultivation and processing facility in Fitchburg, retail locations in Cambridge and Somerville, and a home delivery business. Prior to RC, Keith was CEO of Constant Therapy (CT), a company revolutionizing the treatment of neurological disorders using science-based digital therapy on mobile devices. CT was acquired by a private equity firm in 2017. Prior to CT, Keith was CEO of Connotate (web Big Data aggregation), President of Carbonite (#9 on the Inc. 500 list, Best Places to Work in Boston, Most Innovative Companies in New England, IPO on NASDAQ 2011), CEO of webHancer (acquired by Microsoft), CEO of FaxNet (acquired by Critical Path), and GM of Trans National Communications (#12 on the Inc. 500 list). A graduate of Harvard Business School and Harvard College, Keith lives in Wayland, Massachusetts, with his wife, and has two young adult sons.

Deborah Hasin is an epidemiologist on the faculty at Columbia University, where she has a joint appointment in the Department of Psychiatry, College of Physicians and Surgeons, and the Department of Epidemiology, Mailman School of Public Health. Hasin has a long-standing interest in the national prevalence and time trends in alcohol and drug use and in alcohol, drug, and psychiatric disorders, and in the societal and individual factors affecting these trends. She is also interested in the conceptualization and measurement of substance use disorders and addiction. Hasin has published more than 400 articles, and has had National Institutes of Health funding for studies of alcohol, drugs, and psychiatric disorders since 1990. She is director of the Substance Dependence Research Group at New York State Psychiatric Institute, and also directs the Columbia University pre- and post-doctoral Substance Abuse Epidemiology Training Program (SAETP), now in its sixth year. Hasin is vice president of the American Psychopathological Association, and will be president in 2020. She is on the Board of Directors of the College on Problems of Drug Dependence, and was a member of the National Institute on Alcohol Abuse and Alcoholism National Advisory Council, the DSM-5 Substance Use Disorders workgroup, and the National Institute on Drug Abuse Cannabis Policy Research Workgroup. For lifetime achievement in alcohol epidemiologic research, Hasin received the Jellinek Memorial Award. Her research has been publicized in the lay media, including the BBC, NPR, The New York Times, The Washington Post, and Spectrum News in New York City. She holds a PhD in epidemiology from Columbia University.

Beau Kilmer is a senior policy researcher at the RAND Corporation, where he codirects the RAND Drug Policy Research Center. He also serves as the interim director of RAND San Francisco Bay Area and as a professor at the Pardee RAND Graduate School. His research lies at the intersection of public health and public safety, with special emphasis on crime control, substance use, illicit markets, and public policy. Some of his current projects include assessing the consequences of alternatives to drug prohibition; measuring the effect of 24/7 Sobriety programs on drunk driving, domestic violence, and mortality; and evaluating other innovative programs intended to reduce crime and victimization. Kilmer’s articles have appeared in leading journals, such as American Journal of Public Health, Lancet Psychiatry,New England Journal of Medicine, and Proceedings of the National Academy of Sciences, and his commentaries have been published by CNN, the Los Angeles Times, the New York Times, Newsweek, the San Francisco Chronicle, USA Today, the Wall Street Journal, and other outlets. His coauthored book on cannabis legalization was published by Oxford University Press, and the second edition was released in 2016. Kilmer received a National Highway Traffic Safety Administration Public Service Award for his “leadership and innovation in the areas of alcohol and drug-impaired driving program and policy research,” and his co-authored work on 24/7 Sobriety received honorable mention for the Behavioural Exchange Award for Outstanding Research. Before earning his doctorate at Harvard University, Kilmer received a Judicial Administration Fellowship that supported his work with the San Francisco Drug Court.

Marisa M. Silveri is a behavioral neuroscientist who holds appointments as associate professor of psychiatry at Harvard Medical School and adjunct assistant professor of psychiatry at Boston University School of Medicine. Silveri is the director of the Neurodevelopmental Laboratory on Addictions and Mental Health in the Imaging Center at McLean Hospital. She uses MRI to study teen and emerging adult brain development, with a focus on identifying the neurobiological effects of drug and alcohol use, and identifying the risk factors for later substance abuse and dependence, as well as other psychiatric illnesses. Her work is funded by the National Institute on Alcohol Abuse and Alcoholism, and the John Alden and Mental Insight Foundations. Silveri is the recipient of the Enoch Gordis Research Recognition and the Young Investigator Awards from the Research Society on Alcoholism and the Jack H. Mendelson Memorial Research Award from McLean Hospital. She has authored more than 60 peer-reviewed scientific publications. Silveri served as co-editor of a special issue on the adolescent brain, a collection of 31 peer-reviewed manuscripts in Neuroscience and Biobehavioral Reviews, published in November 2016. She has spoken extensively on the topic of adolescent brain development and the effects of alcohol and drug use on brain function within her local communities; nationally on behalf of the nonprofit organization, the Community of Concern; and nationally and internationally at professional scientific meetings. Silveri holds a BS in biology and psychology from Union College and an MS and a PhD in behavioral neuroscience from the State University of New York at Binghamton.